Posted by Michael Wonder on 26 Sep 2024
Pfizer voluntarily withdraws all lots of sickle cell disease treatment Oxbryta (voxelotor) from worldwide markets
25 September 2024 - Pfizer announced today that it is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease at this time, in all markets where it is approved.
Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
